basiliximab

02/01/2002 - "The efficacy of basiliximab was assessed by conventional parameters, and tolerability was assessed by the incidence of adverse events, infections, and laboratory test result abnormalities. "
07/01/2015 - "Basiliximab resulted in mild infection and a low incidence (10%) of infection-related mortality; ATG resulted in relative severe infection with 29.2% infection-related mortality (P > 0.05). "
04/01/2014 - "Basiliximab and hepatitis C virus infection were independent risk factors for NODAT. "
10/01/2013 - "The use of basiliximab was independently associated with a reduced hazard of HCMV infection/ disease. "
02/01/2013 - "CMV infection was more frequent in female patients (P = 0.044), and those with aGVHD (P = 0.043), using ATG or basiliximab in conditioning regimens (P = 0.049), as well as earlier in patients using ATG or basiliximab or those with aGVHD (P = 0.007; P = 0.000). "

12/01/2002 - "Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation."
11/01/2008 - "To investigate the efficacy of chimeric anti-CD(25) monoclonal antibody (basiliximab) on acute graft-versus-host disease (GVHD) in patients following allogeneic hematopoietic stem cell transplantation. "
10/19/2010 - "To study the feasibility of CD25 monoclonal antibody (basiliximab) in the treatment of severe III-IV intestinal acute graft-versus-host disease (GVHD) following haploidentical hematopoietic stem cell transplantation (HSCT). "
02/01/2009 - "The aim of this study was to investigate the efficacy and feasibility of anti-CD25 monoclonal antibody (basiliximab) in treating steroid-refractory acute graft-versus-host disease (aGVHD) following haploidentical bone marrow transplantation (hiBMT). "
07/01/2015 - "Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis."

07/01/2003 - "Basiliximab appears to be effective at inducing remission in steroid-resistant ulcerative colitis. "
05/15/2006 - "Taken in combination with previously reported data, basiliximab shows particular promise in moderate steroid-resistant ulcerative colitis."
07/01/2003 - "Ten patients with steroid-resistant ulcerative colitis received a single bolus of 40 mg of intravenous basiliximab plus steroid treatment in an open-label, uncontrolled, 24-week study. "
08/01/2012 - "We investigated the efficacy and safety of basiliximab as a corticosteroid-sensitizing agent in patients with corticosteroid-refractory ulcerative colitis (UC). "
05/15/2006 - "We have previously reported a small case series demonstrating the potential of basiliximab as a novel agent for the treatment of steroid-resistant ulcerative colitis. "

03/01/2007 - "In conclusion, this study confirmed the beneficial effects of addition of basiliximab to the immunosuppressive schema of patients with delayed graft function."
11/15/2008 - "The incidence of delayed graft function did not significantly differ between the cohorts (10% and 13%, in basiliximab and control group). "
06/01/2008 - "Basiliximab may reduce the incidence of delayed graft function. "
01/01/2008 - "There was no hyperacute rejection in two groups, and delayed graft function occurred in two patients of ATG group and three of basiliximab group. "
03/01/2010 - "We sought to evaluate the efficacy of renal transplant induction protocols using Basiliximab based on the rates of acute rejection episodes (ARE) and delayed graft function (DGF) of infectious complications in the first 6 months posttransplant, as well as patient and graft survivals. "

02/01/2009 - "The host conditioning with low-dose basiliximab may augment the efficacy of AIT for cancer using activated autologous lymphocytes."
02/01/2009 - "An in vivo study of 9 metastatic cancer patients (7 colorectal and 2 esophageal) demonstrated no subjective or objective adverse effects, even under repeated administration of basiliximab. "
02/01/2009 - "Peripheral blood mononuclear cells (PBMCs) from cancer patients were cultivated in vitro in the presence of a high-affinity chimeric anti-CD25 Ab (basiliximab). "
01/01/2009 - "The main reason for patient death with functioning graft were infectious complications (basiliximab: 3/20, placebo 1/19), 21% of all patients developed cancer without an obvious correlation to specific immunosuppression. "
10/15/2001 - "Nine neoplasms (three in the basiliximab group, six in the placebo arm) were recorded up to 1 year from transplantation. "